Quantitation of the antigenicity and immunogenicity of purified foot-and-mouth disease virus vaccine for swine and steers

Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine

A DNA sequence coding for the immunogenic capsid protein VP3 of foot-and-mouth disease virus A12, prepared from the virion RNA, was ligated to a plasmid designed to express a chimeric protein from the Escherichia coli tryptophan promoter-operator system. When Escherichia coli transformed with this plasmid was grown in tryptophan-depleted media, approximately 17 percent of the total cellular protein was found to be an insoluble and stable chimeric protein. The purified chimeric protein competed equally on a molar basis with VP3 for specific antibodies to foot-and-mouth disease virus. When inoculated into six cattle and two swine, this protein elicited high levels of neutralizing antibody and protection against challenge with foot-and-mouth disease virus.

The effect of acetylethyleneimine upon a strain of inactivated foot-and-mouth disease virus stored at 4 degrees C

The presence of either thiosulphate-neutralized or free AEI was shown to degrade inactivated foot-and-mouth disease virus Type O (Hong Kong) antigen during storage at 4 degrees C. Deterioration was evident after 20 weeks of storage and little antigen remained at 36 weeks. Optimum stability was obtained by removing the residual inactivant immediately after inactivation.

A comparison of some immunological methods for the differentiation of strains of foot-and-mouth disease virus

Two FMDV strains which had been previously differentiated by complement-fixation were compared by guinea-pig protection test, kinetic neutralization and micro-neutralization tests. It was found that these tests, which have not been previously applied by the methods described, were all capable of FMDV strain differentiation. Similar differences were found by all methods, which suggests that comparisons made by cross-CF, cross-neutralization or cross-protection involve measurement of the same antigen/antibody interactions.